Cytokinetics, Incorporated
CYTK
株式のランク
#2267
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
株価
$62.83
最終同期: 2026-10-21
時価総額
$8.73B
変化（1日）
-1.75%
変化（1年）
14.73%
国
US
取引 Cytokinetics, Incorporated (CYTK)
カテゴリー
Healthcare
Cytokinetics, Incorporated（CYTK）の株価履歴
終値の最高値: $62.96 （2026-10-01）
終値の最安値: $97.08 （2004-04-01）
終値の最安値: $97.08 （2004-04-01）
Cytokinetics, Incorporated の株価履歴（2004 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 8.70% |
| 2025 | 28.55% |
| 2024 | 11.95% |
| 2023 | 4.76% |
| 2022 | 4.97% |
| 2021 | 101.81% |
| 2020 | 97.15% |
| 2019 | 42.08% |
| 2018 | -14.22% |
| 2017 | -29.65% |
| 2016 | 4.66% |
| 2015 | 114.65% |
| 2014 | -19.66% |
| 2013 | 59.81% |
| 2012 | -32.39% |
| 2011 | -55.97% |
| 2010 | -23.56% |
| 2009 | 26.62% |
| 2008 | -55.25% |
| 2007 | -26.58% |
| 2006 | -3.72% |
| 2005 | -20.38% |
| 2004 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
